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http:WHAT THIS PAPER ADDS
Peripheral arterial disease (PAD) is an inﬂammatory disease with variable progression and association with
mortality. The routinely collected inﬂammatory marker total white cell count (TWCC) has been associated with
the outcome of a range of inﬂammatory diseases. The value of TWCC in predicting cardiovascular outcome in
patients with peripheral arterial disease is however unclear. This systematic review assessed the published
evidence that TWCC is associated with mortality and major adverse events (MAEs) in PAD patients. Overall, the
current studies suggest a positive but inconsistent association of TWCC with death and MAE. Further rigorous
testing needs to be undertaken before it is clear whether TWCC can provide valuable prognostic information for
PAD patients.Objectives: Peripheral arterial disease (PAD) is principally caused by atherosclerosis, an established inﬂammatory
disease. Total white cell count (TWCC) is a marker of inﬂammation and has been associated with outcomes for
patients with inﬂammatory diseases. The aim of this systematic review was to assess the association of TWCC
with mortality and major adverse events (MAEs) in PAD patients.
Methods: Studies investigating the association of TWCC with outcome in patients with PAD were identiﬁed by a
literature search using the Medline and Cochrane databases. To be eligible for inclusion, studies needed to
investigate the association of TWCC with mortality or a composite endpoint that included mortality in patients
with PAD. Studies were excluded when the primary focus was carotid artery disease, aortic aneurysmal disease,
intracranial vascular disease, or rheumatoid arthritis and treatment with chemotherapy or transplantation of
stem cells. Secondary searching of reference lists and relevant reviews was performed.
Results: Ten studies including 8,490 patients with PAD met the inclusion criteria. All studies investigated more
than 100 patients with four studies assessing more than 1,000 patients. Study quality varied with well-
established risk factors of outcome such as age, smoking, diabetes, and the ankle brachial index being adjusted
for inconsistently. The study populations were also disparate. Few studies reported relative risk and 95%
conﬁdence intervals for the association of TWCC with mortality or MAE. TWCC was positively and signiﬁcantly
associated with death alone in four of ﬁve studies investigating 3,387 patients. TWCC was positively and
signiﬁcantly associated with MAE in ﬁve of six studies investigating a total of 6,846 patients.
Conclusions: Current evidence suggests a positive association of TWCC with mortality and MAEs in patients with
PAD. Further well-designed prospective studies are required with high-quality analysis and more complete
reporting of outcomes.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Peripheral arterial disease (PAD) is one manifestation of the
inﬂammatory disease atherosclerosis, characterized by
arterial stenosis and occlusions of peripheral arteries.1 PAD
prevalence is approximately 29% in people aged 70 years or
older or those aged over 55 years with risk factors of
smoking or diabetes.2 Inﬂammation plays a key role in the
development, progression, and complications of athero-
sclerosis. Inﬂammatory processes interacting with endo-
thelial dysfunction initiate a progressive process within the
arterial wall, resulting in reduction or obstruction of blood
supply to end organs of the body including brain, heart,
intra-abdominal organs, and the tissues of the lower limbs,
causing morbidity and mortality.3e5 Patients with PAD have
up to six times the 10-year mortality of age-matched con-
trols.6,7 The presence of either symptomatic or asymp-
tomatic PAD is an indicator of diffuse and signiﬁcant disease
in all arterial beds,8 including coronary and cerebral ar-
teries, and associated with a high cardiovascular event
rate.9 Predicting the risk of cardiovascular events in in-
dividuals with PAD enables management to be tailored
appropriately, for example by intensifying medical man-
agement or offering lower risk operative or endovascular
management. Established predictors of outcome for pa-
tients with PAD include age,10 gender,11 smoking,12 dia-
betes,13 ankle brachial index (ABI),14 and medications
including antiplatelet therapy15 and HMG-CoA reductase
inhibitors (statins).16 Markers of inﬂammation are well-
established risk predictors in patients with coronary heart
disease3,6,17 but have been relatively less well investigated
in patients with PAD.
PAD patients have increased circulating markers of
inﬂammation compared with the population without this
disease.18,19 Total white cell count (TWCC) assessed within a
peripheral venous sample is recognized as a marker of
inﬂammation and altered concentrations of monocytes and
neutrophils have been implicated in atherosclerosis.5
Leukocytosis has been associated with reduced survival in
patients with coronary heart disease.20 TWCC has been
shown to be a reliable predictor of outcome in patients with
stable coronary heart disease21 or acute coronary syn-
drome,22,23 and after coronary artery bypass grafting
(CABG)24e28 or percutaneous coronary intervention
(PCI).29e31 TWCC also predicts mortality in other surgical32e
36 and cancer37e40 patients.
It has been suggested that risk stratiﬁcation models of
PAD patients should combine clinical risk factors, clinical
stage of disease, a measure of PAD severity (ABI), and a
measure of systemic inﬂammation.41 TWCC is routinely
measured in patients with PAD and could be added to
models used to predict outcome for these patients. The
independent association of TWCC with outcome in PAD
patients has however not previously been systematically
examined. The aim of this systematic review was to examine
the association of TWCC with mortality and the composite
endpoint of major adverse events (MAE) in patients with
PAD.METHODS
Protocol
The preferred reporting items for systematic reviews and
meta-analysis (PRISMA) guidelines42 and meta-analysis of
observational studies in epidemiology (MOOSE) proposal43
were followed using a standardized written protocol.
Searching and study selection was conducted indepen-
dently by two investigators.Search criteria
A literature search was performed of articles published be-
tween 1 January 1946 and 1 November 2013. Databases
searched included Medline (via Pubmed and Ovid SP 1946 to
present including in-process and non-indexed citations), and
the Cochrane Database of Systematic Reviews. The search
was conducted using the following terms: (“Arteriosclerosis”
OR “Peripheral Arterial Disease” OR “Peripheral Vascular
Disease” OR “Arterial Occlusive Disease”) AND (“Leucocyte
Count” OR “Leukocyte Count”) with prior checking in the
MeSH database to include synonyms. All subheadings were
included in the searches. Publications selected for inclusion
had their keywords searched manually to ensure no alter-
native expression or relevant keywords were unintentionally
excluded. Reference lists from included publications and
relevant literature reviews were also examined to increase
the yield of possible studies. Studies identiﬁed in the latter
way are shown in Fig. 1 as additional records.Eligibility criteria
For inclusion in this review studies needed to assess the
association of TWCC with mortality or a composite of
endpoints, including death in patients with PAD. Only
publications in English were included. Studies were
excluded when the primary focus was carotid artery dis-
ease, aortic aneurysmal disease, intracranial vascular dis-
ease, rheumatoid arthritis, or treatment with chemotherapy
or transplantation of stem cells.Data extraction
Data were extracted from included studies by two indepen-
dent investigators. Information collected included study
design; participant proﬁle including age, gender, cardiovascu-
lar risk factors,medications, andmethodofmeasuring severity
of occlusive PAD; study inclusion and exclusion criteria; and
duration of follow-up. The endpoint deﬁnitions with type and
incidence of events were recorded. The method of statistical
analysis and subsequent results were also recorded. Datawere
standardized to include both event numbers and percentages
of the relevant study population where possible. Potential
sources of bias or conﬂict of interest were recorded.Data analysis
Data was transcribed into a Microsoft Excel worksheet. Any
discrepancies between investigators were reviewed by the
author panel until a consensus was reached. No published
Figure 1. PRISMA ﬂowchart.
424 D. Martin et al.quality assessment tool was found to assess study quality in
PAD. Therefore, a novel quality assessment tool was
developed to assess the risk of bias.44 The tool was
designed to assess the inclusion of speciﬁc confounding
variables relevant to PAD within individual studies to enable
comparison between studies. Risk of bias in methodology or
reporting was estimated by assessing sample size, whether
established risk factors for outcome in PAD were adjusted
for in analyses and follow-up time (Table 1).
RESULTS
Study selection
Searching identiﬁed a total of 688 articles in Medline and
927 in PubMed (Fig. 1). No relevant reviews were found inTable 1. Risk of bias assessment tool.
Risk of
bias
Sample
size
Confounding variables adjusted (univariate/multi
Gender Age Smoking
High <100 Not reported Not reported Not reported
Not statistically
adjusted
Not statistically
adjusted
Not statistically
adjusted
Medium >100
< 1000
Recorded not
reported
Recorded not
reported
Recorded not
reported
Statistical
adjustment
unclear
Statistical
adjustment
unclear
Statistical
adjustment
unclear
Low >1000 Reported Reported Reported
Statistically
adjusted
Statistically
adjusted
Statistically
adjustedthe Cochrane database of systematic reviews. After
combining with 1,170 additional articles, the 969 duplicates
were removed. A total of 1,782 articles screened did not
meet the inclusion criteria. Thirty-four full text articles were
reviewed. Three studies investigating the association of
TWCC with the presence of PAD without any assessment of
the incidence of morbidity or mortality of patients with PAD
were excluded (labeled epidemiology in Fig. 1). Twelve ar-
ticles were excluded for the following reasons: measure-
ment of neutrophilelymphocyte ratio without TWCC;45
inclusion of TWCC but no test for the association with
mortality or a composite endpoint including mortality;46
investigation of thoracic endovascular aneurysm repair pa-
tients, which are a separate subset of the PAD population;47
outcome measures did not include mortality or a compositevariate) Follow-up
Diabetes
mellitus
Medications Ankle brachial
index
Not reported Not reported Not reported <1 year
Not statistically
adjusted
Not statistically
adjusted
Not statistically
adjusted
Recorded not
reported
Antiplatelet
and statin
reported
Recorded not
reported
1e2 years
Statistical
adjustment
unclear
Statistical
adjustment
unclear
Statistical
adjustment
unclear
Reported Reported Reported >2 years
Statistically
adjusted
Statistically
adjusted
Statistically
adjusted
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with endpoints of clinical importance such as graft occlu-
sion, myocardial infarction, stroke, or patients requiring
arteriography.53 Ultimately, 10 studies were included in this
systematic review.54e63
Study quality
The assessment of bias data for all the selected studies are
shown in Table 2. All selected studies involved more than
100 patients, with four studies including more than 1,000
patients.54,57,59,63 Most studies adjusted for gender in sta-
tistical analysis although adjustment for other variables was
less consistent, with neither Belch et al.58 or Violi et al.63
reporting adjusting for age. Smoking has a well-
established association with TWCC and mortality but was
not adjusted for in two studies,54,56 while Arain et al.55
reported adjusting for smoking status but did not publish
details. Diabetes was not adjusted for in two included
studies54,58 despite evidence that PAD patients with dia-
betes have higher rates of mortality than PAD patients
without diabetes.13,64 The trend for included papers to not
report or adjust for medications and ABI raises the possi-
bility of bias in the included studies. Medication adjustment
was reported in only four of the 10 studies,55,56,60,61 with
the remaining papers not adjusting for antiplatelet or statin
use, both of which have been reported to be associated
with reduced cardiovascular events in PAD patients.16,65
ABI, an objective measure of disease severity with previ-
ously demonstrated association with cardiovascular
events,14,66e68 was not adjusted for in ﬁve54,56e58,62 of the
10 studies.54e63 Pedrinelli et al.62 reported adjusting for all
signiﬁcant variables in a step-wise regression analysis,
although details were not included in the report. AmarantoTable 2. Assessment of risk of bias.
Risk of bias Sample size Confounding variable adjust
Gender Age S
Amaranto et al.54 Low Low Low H
Low Low H
Arain et al.55 Medium Low Low H
Low Low L
Barani et al.56 Medium Low Low L
Low Low H
Belch et al.58 Medium Low High L
Low High L
Bhutta et al.57 Low Low Low M
Low Low L
Dormandy et al.59 Low Low Low L
Low Low L
Giugliano et al.60 Medium Low Low L
Low Low L
Haumer et al.61 Medium Low Low L
Low Low L
Pedrinelli et al.62 Medium Low Low L
Medium Medium M
Violi et al.63 Low Low Low L
Low High L
Note. ABI ¼ ankle brachial index; DM ¼ diabetes mellitus.
a Statin alone.et al.54 adjusted for the least confounding variables (i.e.
gender and age alone), while two studies, namely those
reported by Arain et al.55 and Giugliano et al.,60 adjusted for
all included confounding variables. Only one study had a
follow-up of less than 1 year with follow-up being only 6
months.58 Three studies had follow-up of more than 2
years.55,57,60Characteristics of included studies
All investigations were cohort design and eight of the 10
were prospective,55,56,58e63 with the remaining two studies
involving retrospective examination of prospectively main-
tained databases.54,57 Six studies54e57,61,62 investigated the
endpoint of all-cause mortality although Dormandy59 did
not provide information on the association of TWCC and all-
cause mortality so was unable to be included in this section
of the analysis. Six studies used composite outcomes with
varying deﬁnitions shown in Table 3.54,58e61,63 MAE was the
most common composite outcome consisting of myocardial
infarction (MI), stroke, and death or vascular death in four
studies.54,60,61,63 An amputation score used by Belch et al.58
gave a weighted score to amputation and death. Violi
et al.63 used a composite endpoint that in addition to MAE
included major amputation and excision of ischemic viscera.Characteristics of included participants
The 10 included studies had a total of 8,490 patients with
PAD. There was marked heterogeneity between studies
with respect to the included participant groups (Table 3).
Patients recruited included those undergoing major open
vascular surgery54,57 or major endovascular surgery,54 with
critical limb ischaemia,56,58,62 with intermittentment in statistical analysis Follow-up
moking DM Medications ABI
igh Low High High Medium
igh High High High
igh Low Low Low Low
ow Low Low Low
ow Low Low Low Medium
igh Low Low High
ow High High High High
ow High High High
edium Low High High Low
ow Low High High
ow Low High Low Medium
ow Low High Low
ow Low Low Low Low
ow Low Low Low
ow Low Mediuma Low Medium
ow Low Mediuma Low
ow Low High High Medium
edium Medium High High
ow Low High Low Medium
ow Medium High Low
Table 3. Study characteristics.
Author Sample
size
Cohort
design
Inclusion criteria Exclusion criteria Primary endpoint Secondary
endpoint
Follow-up
(months)
Amaranto
et al.54
1773 *a Major vascular surgery:
Endovascular: CAS, T/EVAR,
LES (804)
Open: CEA, T/AAA, LEB (969)
“Major” elective endovascular or open
intervention within 30 days of vascular
index procedure, No pre-op TWCC,
TWCC outside normal range
Death, MAE, TIA, infection,
bleeding, reoperation and
amputation
Death
MAE ¼ death, stroke
and MI
14b
Arain et al.55 226 ** Referral for lower-extremity
vascular evaluation
ABI >1.3, not consented,
lost to follow up
All-cause mortality e 71b
Barani et al.56 259 ** Admission with critical limb
ischaemia
No written consent All-cause mortality Vascular death 12
Belch et al.58 366 ** Critical limb ischaemia Infection Amputation score 1e7c e 6
Bhutta et al.57 1021 *a Major vascular surgery
(CEA, EVAR, open AAA, LEB)
Fistula formation, vascular trauma,
mesenteric revascularization,
thoracic aneurysm
Death within 2 yrs e 24
Dormandy
et al.59
1969 ** Claudication, ABI < 0.85 in both
arteries of at least one leg or
revascularized patients
Platelet active drugs, b blockers,
rest pain or gangrene
All-cause mortality MAE ¼ MI, stroke
and vascular death
12
Giugliano
et al.60
259 ** ABI < 0.9 selected from patients
referred to vascular lab (365)
ABI > 0.9; critical limb ischaemia;
revascularization < 6/12; unstable
angina, MI or stroke in last 3/12;
decompensated heart failure;
cancer; hepatic, renal or inﬂammatory
disease. TWCC > reference range
MI, stroke (including
fatal)
30b
Haumer et al.61 398 ** >50% stenosis on
angiogram of
symptomatic limb
(Consecutive admissions
to ward)
Acute infection unrelated to PAD,
missing data or TWCC, no follow-up
Death, MI, PCI,
CABG, stroke, carotid
operation
Death alone
MAE ¼ death,
stroke and MI
20b
Pedrinelli et al.62 108 ** Critical Limb Ischaemia
undergoing angiogram
Patients on oral anticoagulants or
ﬁbrates at baseline
All-cause mortality e 19.2b
Violi et al.63 2111 ** Claudication, ABI
< 0.8 in one foot,
previous amputation
or revascularization
surgery
Antiplatelet, anticoagulant or NSAIDs,
rest pain or ulcer, MI, stroke or surgical
intervention <3/12, angina requiring
CABG or PCI, liver insufﬁciency, renal
disorders or life expectancy <2 yrs,
patient withdrew, adverse events,
concomitant disease, therapy refusal,
antibiotics, >80 yrs
Major: Death, MI, stroke,
excision of ischemic viscera,
major amputation
Minor: angina, MI,
TIA, minor stroke,
renal failure, HTN,
vascular surgery,
PTA/thrombolysis
18
Note. ABI ¼ ankle brachial index; CABG ¼ coronary artery bypass grafting; CAS ¼ carotid artery stent; CEA ¼ carotid endarterectomy; HTN ¼ hypertension; LEB ¼ lower extremity bypass;
LES ¼ lower extremity stent; MAE ¼ major adverse event; MI ¼ myocardial infarction; PAD ¼ peripheral arterial disease; PCI ¼ percutaneous coronary intervention; PTA ¼ percutaneous
transluminal angioplasty; T/AAA ¼ open thoracic or abdominal aortic aneurysm repair; T/EVAR ¼ thoracic or abdominal endovascular aneurysm repair; TIA ¼ transient ischemic attack;
TWCC ¼ total white cell count; NSAIDs ¼ non steroidal anti-inﬂammatory drugs.*Retrospective.**Prospective.
a From prospectively maintained database.
b Median.
c Amputation score: 1 ¼ no amputation to 7 ¼ hip disarticulation or death.
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vestigations.55,61 The variation in the study populations of
PAD patients was further demonstrated in the wide range
of participant characteristics (Table 4). The inclusion of male
subjects varied from 50% to 93%.56,57 The average age of
included patients was also widely ranging varying from 63
to 80 years.56,63 The prevalence of smokers ranged from
25% to 77%,56,60 although the deﬁnition varied across
studies with Belch et al.58 putting both current and previous
smokers in the same group, but Pedrinelli et al.62 recording
both current and former smokers separately. The prevalence
of hypertension varied from 35% to 84%,54,63 hyper-
cholesteremia from 47% to 82%55,61 and diabetes from 25%
to 57%.55,56 A history of previous MI was present in only 2%
of the patients in the study reported by Amaranto et al.,54
whereas 54% of the patients in the investigation of Arain
et al.55 had a history of coronary artery disease or cere-
brovascular disease. The severity of PAD as assessed by ABI
was reported in six studies.55,56,59e61,63 In the study of
Dormandy59 16% of patients had an ABI <0.05 despite
clinically being graded as Rutherford stage 1e3. In the study
of Barani et al.56 mean ABI was 0.31 and 28% of the non-
survival group presented with gangrene, in contrast to the
study of Arain et al.,55 where 53% had an ABI >0.9. Renal
impairment was reported in only two studies.54,56
Association of TWCC with death
The association of TWCC with death alone was reported in
ﬁve studies including 3,387 patients (Table 5).54e57,62 Four
studies, including 2,366 patients, reported a positive asso-
ciation of TWCC with death after adjusting for other risk
factors.54e56,62 One study did not report an adjusted anal-
ysis because TWCC was not associated with death on uni-
variate analysis.57 In the two studies that examined major
open vascular surgical procedures54,57 neither demon-
strated a signiﬁcant linear association between TWCC and
death but when a quadratic term was used for TWCC in the
study reported by Amaranto et al.54 a signiﬁcant association
was demonstrated. Odds or hazard ratios were reported in
only four studies, and54e57 conﬁdence intervals were only
published in three studies;55e57 consequently, meta-
analysis was not possible. One study that did demonstrate
an association57,62 between TWCC and death did not pub-
lish their method of multivariate statistical analysis. Only
one study55 adjusted for all confounding variables, and this
study reported the most positive association of TWCC with
death (risk ratio of 3.72).
Association of TWCC with MAE
The association of TWCC with MAE was assessed in six
studies including 6,846 patients (Table 6).54,58e61,63 The
composite outcome of MAEs deﬁned as death, MI, or stroke
was positively associated with TWCC in ﬁve54,58e60,63 of the
six included studies although deﬁnitions for inclusion in this
group varied between studies. Three studies published an
odds or hazard ratio54,58,60,63 and one study relative risk,58
but only three published conﬁdence intervals.58,60,63 Theonly study reporting no association between TWCC and
MAE61 did not publish any results other than reporting no
signiﬁcant association. As a result of the above-mentioned
inconsistencies meta-analysis was not possible. Three
studies reporting a positive association54,58,63 had a high
risk of bias in three or more sections of the assessment tool
(Table 1). The remaining two positively associated studies
had less marked risk of bias noted. Dormandy59 did not
report adjustment for medication alone. The study reported
by Giugliano et al.60 had the lowest risk of bias of all
included studies. The investigation that reported no asso-
ciation between TWCC and MAEs adjusted for all con-
founding risk factors except aspirin.61 The study reported by
Haumer et al.61 had the broadest outcome inclusion criteria,
including PCI, CABG and carotid operations together with
other MAEs making direct comparison problematic.DISCUSSION
There is a current deﬁciency in predictive markers of
outcome for PAD patients. TWCC is a recognized marker of
systemic inﬂammation in many diseases. In the current
systematic review we assessed the association of TWCC
with death and MAEs in PAD patients. Overall, the current
studies suggest a positive but inconsistent association of
TWCC with death and MAEs.
Predicting the PAD patients who will die is clinically
important, and prognostic indicators of risk have been
proposed to include clinical risk factors, stage of disease,
and circulating biomarkers for these models to be accurate
predictors of outcome.41 Before these models are adopted
in the clinical setting they need to be rigorously tested in
studies using consistent deﬁnition of terms and thorough-
ness in adjusting for other known confounders.
A major ﬁnding of this review was the heterogeneity of
reported studies, with great variation in the included pa-
tients and their characteristics, making compilation of re-
sults challenging. This emphasizes the importance of
adjusting for established confounding variables and fully
reporting the results of adjusted analyses. Without this in-
formation a meta-analysis of collated studies was not
possible. While adjustment for some confounders was
consistent between studies with all studies adjusting for
gender, and all studies except those reported by Belch
et al.58 and Violi et al.63 adjusting for age, the known con-
founders of medication and ABI were poorly adjusted for in
the selected studies. Pedrinelli et al.62 reported the con-
founders of gender, age, smoking, and diabetes, although it
was unclear whether these variables were adjusted for in
their statistical analysis. The only selected study to adjust
for all confounders in the assessment tool was Arain et al.,55
who reported the strongest association of TWCC with
death. Giugliano et al.60 was the highest quality study with
the lowest assessed risk of bias, and reported the strongest
positive association of TWCC with MAE.
Variation in the deﬁnition of MAEs was another key
ﬁnding. The endpoint of death, stroke, and MI (MAEs) (þ/
CABG, þ/ PCI) was used in three studies but in one study
Table 4. Participant characteristics.
Author Group Cases Male Age Smoking HTN Cholesterol DM Previ s
MI
ABI Severity of
PAD
Renal
impairment
Amaranto
et al.54
Endo 804 580 (71%) 71.2  10.4 NR 677 (83.3%) 485 (60%) 203 (25.1%) 20 (2 %) NR NR 99 (12.3%)
Open 969 617 (63%) 69.6  10.5 NR 822 (84.3%) 618 (63.4%) 251 (25.7%) 19 (1 %) NR NR 106 (10.9%)
Arain
et al.55
Cohort 226 121 (54%) 68.4  11 137 (61%) 150 (66%) 105 (47%) 56 (25%) 122 %)a <0.9 ¼ 114
(50%)
NR Measured
NR
Barani
et al.56
Survivor 198 99 (50%) 74  10 69 (35%) 141 (71%) HDL and
LDL reported
100 (51%) NR 0.31  0.21 Gangrene
16 (8%)
1 (0.5%)
Non
Survivors
61 39 (64%) 80  10 15 (25%) 40 (66%) HDL and
LDL reported
35 (57%) NR 0.32  0.26 Gangrene
17 (28%)
4 (7%)
Belch
et al.58
Cohort 366 221 (60%) NRb 244 (66%)c NR NR NR NR NR NR NR
Bhutta
et al.57
Cohort 1021 944 (93%) 71  8.45 191d d NR d d,e NR NR NR
Dormandy
et al.59
Cohort 1969 1572 (80%) 63.2  9.1 1396 (71%) 1113 (57%) Mean 6.5
mmol/L  1.5
277 (14%) 203 %) <0.05 ¼ 316
(16%),
>0.85 ¼ 189
(10%)
F ¼ II NR
Giugliano
et al.60
Cohort 259 196 (76%) 66.9  9.1 199 (77%)c 212 (82%) 200 (77%) 125 (48%) 115 %) 0.69  0.18 F ¼ II NR
Haumer
et al.61
NC  5.8
g/L
136 86 (63%) 65 (57e75)* 77 (57%) 101 (74%) 100 (74%) 62 (46%) 35 (2 ) 0.56
(0.41e0.71)*
CLI 36
(27%)
NR
NC  5.8
g/L
262 147 (56%) 71 (60e76)* 94 (36%) 196 (75%) 215 (82%) 95 (36%) 63 (2 ) 0.59
(0.45e0.75)*
CLI 53
(20%)
NR
Pedrinelli
et al.62
Cohort 108 78 (72%) 72  10 73 (68%)c 88 (82%) 51 (47%) 41 (38%) 33 (3 )f 0.3 (0e0.6)
n ¼ 55
F ¼ III
27 (25%)
F ¼ IV 81
(75%)
NR
Violi
et al.63
Cohort 2111 1764 (84%) 63  0.16** 718 (34%) 745 (35%) NR 397
(19%)
NR <0.8 ¼ 1021
(48%)
F ¼ II NR
Endo ¼ endovascular; NR ¼ not reported; F ¼ Fontaine classiﬁcation system; HTN ¼ hypertension; DM ¼ diabetes mellitus; MI myocardial infarction; ABI ¼ ankle brachial index;
PAD ¼ peripheral arterial disease; NC ¼ neutrophil count; HDL ¼ high density lipoprotein; LDL ¼ low density lipoprotein; CLI ¼ crit l limb ischemia.*Interquartile range.**SEM.
a Coronary artery disease OR cerebrovascular disease.
b Age not reported but adjusted for in linear regression.
c Smokers includes current smokers and previous smokers.
d Recorded, univariate regression reported.
e Ischemic heart disease or cardiac failure.
f Self-reported MI, angina or use of nitroglycerine, deﬁnite MI on resting ECG, self-reported history of coronary PCI or CABG.
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Table 5. Association between white cell count and mortality in peripheral arterial disease patients.
Author Population Cases Analysis RR/OR/HR 95% CI p Adjusted
Amaranto et al.54 Major endovascular
surgery
804 a OR ¼ 1.82 NR .015 Age, gender, diabetes, CHF, MI, renal
impairment, HTN, lipids, emergent
procedure
Major open vascular
surgery
969 a OR ¼ 1.168 NR .005c Age, gender, diabetes, CHF, MI,
renal impairment, HTN, lipids,
emergent procedure
Arain et al.55 Lower extremity
evaluation
226 b HR ¼ 3.37 1.56e7.27 NR Age, gender, smoking, hypertension,
CAD/CVD, serum creatinine,
ABI & CRP
Subset ABI <0.9 114 b HR ¼ 3.72 1.38e1.01 NR Age, gender, smoking, hypertension,
CAD/CVD, serum creatinine, ABI and
CRP
Barani et al.56 CLI 259 a OR ¼ 1.202 1.054e1.370 .006 NR
Bhutta et al.57 Major vascular
surgery
1021 NR OR ¼ 1.02 0.95e1.09 .54 Univariate regression only
Pedrinelli et al.62 CLI 108 NR NR NR <.04 NR
ABI ¼ ankle brachial index; CAD ¼ coronary artery disease; CHF ¼ congestive heart failure; CLI ¼ critical limb ischaemia;
CVD ¼ cerebrovascular disease; HR ¼ hazard ratio; HTN ¼ hypertension; MI ¼ myocardial infarction; NR ¼ not reported; NS ¼ not
signiﬁcant; OR ¼ odds ratio; RR ¼ relative risk; CRP = C reactive protein.
a Per 1000/mL increase.
b Top tertile compared with bottom tertile.
c Quadratic term for white cell count.
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included in MAEs.60 Some investigators included reinter-
vention such as revascularization with bypass or endovas-
cular surgery or major amputation with MAEs. An agreed
international deﬁnition for MAE in PAD patients would
assist literature review and comparison of reported series.
There is evidence that TWCC may better predict outcome
in endovascular interventions and lower limb operations
than when combining all major vascular operations
including aortic and carotid surgery. Two studies investi-
gating patients undergoing angiogram or major endovas-
cular interventions were able to demonstrate an association
between TWCC and outcome on both univariate and
multivariate analyses.54,62 A similar result was seen in a
study that focused on lower limb bypass,49 although the
sample size was small and the outcome was MI in isolation
rather than a composite outcome thus not meeting inclu-
sion criteria for this review. TWCC was not linearly associ-
ated with mortality of patients undergoing major open
vascular surgery in two large groups,54,57 though when a
quadratic term was used for TWCC54 a signiﬁcant associa-
tion with death was found, raising the possibility of a more
complex relationship in these patients which will need to be
considered in statistical analyses in the future. There are
many potential confounders in open operations for aortic
and carotid disease and in this patient group it may be more
appropriate to examine these interventions separately in
the future.
The timing of blood sampling in relation to surgical
intervention was variable in the included studies. In one
study the most recent TWCC prior to the procedure54 was
used, while in some investigations timing was not speciﬁed.
Both Violi et al.63 and Dormandy59 included patients that
previously had arterial reconstructive surgery withoutreporting the timing of this surgery relative to study entry.
Ulceration, tissue loss, and gangrene of the lower limb are
all potential confounders of TWCC in patients with PAD.
None of the studies focusing on CLI reported differentiating
rest pain from gangrene.56,58,61 None of the included
studies adjusted for antibiotic use, and only in the investi-
gation reported by Violi et al.63 were patients on antibiotics
excluded.
The limitations of this review include the small number of
studies identiﬁed and the heterogeneous nature of pop-
ulations studied and endpoint deﬁnitions. TWCC is the most
commonly measured inﬂammatory marker that has been
associated with the clinical outcomes of atherosclerotic
disease, although its use for risk stratiﬁcation remains un-
proven in the PAD population. It has been suggested that
risk factor modiﬁcation and targeted medical therapy in the
high-risk population would be of beneﬁt,1,69,70 and that
prognostic modeling that identiﬁes high-risk patients may
increase patient compliance to lifestyle change and phar-
macologic therapy. The relationship between TWCC and
speciﬁc outcomes within deﬁned subgroups of the PAD
population based on stage of disease requires further study
before it can be used in modeling to predict outcome.
Further analysis of differential WCC should be undertaken in
the same manner, to assess its value in determining high-
risk patients for targeted interventions. Future studies
should also standardize reporting, including timing of blood
sampling, infection or tissue loss in the limb, antibiotic us-
age at the time of sampling, and the timing and method of
revascularization in relation to sampling.
In conclusion, this systematic review demonstrated a
positive but inconsistent association of TWCC with death
and MAEs in patients with PAD. If TWCC is associated with
death and MAEs in higher quality large studies as a readily
Table 6. Association between white cell count and major adverse events in peripheral arterial disease patients.
Author Population Cases Endpoint Analysis RR/OR/HR 95% CI p Adjusted
Amaranto
et al.54
Major
endovascular
surgery
804 MAE * OR 1.672 NR .001 NR
Major open
vascular
surgery
969 MAE * OR 0.58 NR .580 NR
MAE*** * OR 1.07 NR .119 NR
Belch
et al.58
CLI 366 Amputation
scorea
9  109/L RR 1.6 1.2e2.0 .001 Gender, smoking,
prostacycline
Dormandy
et al.59
Claudication 1969 MAE NR NR NR .05 NR
Giugliano
et al.60
Claudication 259 MAE * HR 1.35 1.10e1.65 <.01 Age, gender, ABI,
smoking, diabetes
mellitus,
hypercholesteremia,
hypertension,
previous MI and
previous stroke
HR 1.29 1.06e1.57 <.02 Medications
MAE ROC and Bootstrap
groups >7.7  109
compared to
7.7  109
HR 3.03 1.38e6.61 .005 log
rank
Age, gender, ABI,
smoking, diabetes
mellitus,
hypercholesteremia,
hypertension,
previous MI and
previous stroke
HR 2.58 1.21e5.49 Medications
MAE ABI 0.63 and
TWCC >7.7  109
compared to
ABI  .63
and TWCC
<7.7  109
HR 5.77 2.04e16.34 .010 NR
Haumer
et al.61
Inpatient
angiograms
368 MAE ** NR NR .22 NR
Violi
et al.63
Claudication,
previous
amputation
or bypass
2111 MAE þ excision
of ischemic
viscera,
amputation
above the ankle
Population
standardized
odds ratio
OR 1.15 1.023
(90%)
to 1.301
(09%)
.0507
Note. ABI¼ ankle brachial index; CLI ¼ critical limb ischaemia; HR ¼ hazard ratio; MAE ¼major adverse event; MI¼myocardial infarction;
NR ¼ not reported; NS ¼ not signiﬁcant; OR ¼ odds ratio; RR ¼ relative risk; ROC = receiver operating characteristic; TWCC = total white
cell count.*Per 1000/mL increase.**Top compared with bottom tertile.***Quadratic term for white cell count.
a Amputation score graded 1e7 (1 no amputation to 7 hip disarticulation or death).
430 D. Martin et al.obtainable marker of inﬂammation, it may be easily inte-
grated into predictive models of outcome for PAD patients.
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